AgingResearch.NewsJoin free

Newsoara

CompanyChina

Newsoara develops one asset, in phase 3 (prifemilast in psoriasis). Mostly small molecule acting on inflammation, PDE4B and PDE4D; based in China.

1
Asset
Furthest stage
Phase 3
0
Trials
2
Signals

Pipeline

1

  • prifemilast

    Inhibits PDE4, increasing intracellular cyclic AMP and suppressing inflammatory signaling.

    Phase 3, Small molecule, Inflammation, PDE4B, psoriasis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Signals2
  • Similar companies6

Intelligence